公开(公告)号：WO2023079137A1

公开(公告)日：2023-05-11

申请号：PCT/EP2022/080965

申请日：2022-11-07

Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN ,  VIB VZW ,  UNIVERSITEIT GENT

Inventor： GEUKENS, Nick ,  DECLERCK, Paul ,  IMBRECHTS, Maya ,  AMPOFO, Louanne ,  MAES, Wim ,  NEYTS, Johan ,  ABDELNABI, Rana ,  EECKHAUT, Hannah ,  CALLEWAERT, Nico ,  FIJALKOWSKA, Daria

IPC: C07K16/10 ,  A61K39/395 ,  A61P31/14 ,  C12N15/13 ,  A61K2039/505 ,  A61K2039/53 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to antibodies or antigen binding fragments thereof, specifically binding to the trimeric spike protein of Wuhan Covid-SARS-2 and specifically binding to the RBD domain of all of Wuhan, alpha, beta, gamma, delta and omicron variant of Covid-SARS-2 spike protein, characterized in that said antibody or antigen binding fragment thereof has an IC50 in a SARS-CoV-2 pseudovirus infection lower than 1 nm in a SARS-CoV-2 pseudovirus infection, and in that said antibody or antigen binding fragment thereof has an affinity for RBD domain Wuhan Covid-SARS-2 spike protein with a KD of less than 500 pM, and in that said antibody or antigen binding fragment thereof has an affinity for trimeric spike protein of Wuhan Covid-SARS-2 with a KD of less than 300 pM.

公开(公告)号：WO2015118147A1

公开(公告)日：2015-08-13

申请号：PCT/EP2015/052624

申请日：2015-02-09

Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  Université de Caen Basse Normandie ,  Centre Hospitalier Universitaire de Caen

Inventor： DECLERCK, Paul ,  DE MEYER, Simon ,  GEUKENS, Nick ,  GILS, Ann ,  RUBIO, Marina ,  VIVIEN, Denis ,  WYSEURE, Tine

IPC: C07K16/38 ,  C07K16/46

CPC classification number: C07K16/38 ,  A61K2039/505 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/76 ,  G01N2800/22

Abstract: Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).

Abstract translation: 本文公开了用于治疗血栓形成障碍的双特异性抑制剂，例如急性血栓形成障碍如中风和血栓栓塞。 双特异性抑制剂基于靶向TAFI和PAI-1的单克隆抗体，并且在纤溶酶原激活剂如组织型纤溶酶原激活物（tPA）的存在或不存在下显示有效性。